Tirzepatide activates brown adipose tissue to directly burn metabolic energy in mice, according to a study led by Marion Peyrou, a Ramón y Cajal researcher at the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB), the Sant Joan de Déu Research Institute (IRSJD), and the CIBER in Physiopathology of Obesity and Nutrition (CIBEROBN). The findings offer new clues regarding how the dual-receptor drug influences body weight and metabolic health beyond simple appetite suppression.
How Tirzepatide Targets Hormone Receptors
Tirzepatide, sold under the brand name Mounjaro for treating poorly controlled type 2 diabetes mellitus and approved for weight management in adults with obesity or overweight with comorbidities, targets the receptors for two hormonal factors simultaneously: GIP and GLP-1. This dual mechanism produces substantial weight loss largely by reducing food intake. To determine whether the drug also triggers metabolic changes independent of calorie restriction, Peyrou’s research team utilized an experimental mouse model.
Obese mice fed a high-fat diet received tirzepatide treatment and were compared against a control group of mice that did not receive the drug but were given the same amount of food. By controlling calorie consumption across both groups, the scientists isolated the direct physiological effects of tirzepatide from the metabolic consequences of eating less.
Activation of Calorie-Burning Brown Fat
The tissue analysis revealed that tirzepatide activated brown adipose tissue, which specializes in using energy and burning calories from food, contrasting with white adipose tissue that primarily stores fat. Marion Peyrou stated that this activation links to an increased capacity to burn metabolic energy alongside the production of beneficial batokines.
“This drug not only reduces body weight, but also has beneficial effects on metabolism,” Peyrou noted, explaining that active brown fat burns glucose and fat within the body, contributing to lower blood glucose and fat levels.
Implications for Obesity and Cardiovascular Health
While previous pharmacological attempts to activate brown fat triggered unwanted side effects, particularly those affecting the heart, tirzepatide demonstrated cardiovascular benefits alongside brown fat activation. Peyrou indicated that if these findings translate to human patients, future therapeutic strategies might focus on increasing energy expenditure alongside reducing food intake.
The researchers emphasize caution, noting that mouse metabolism, fat tissue distribution, and drug responses differ substantially from humans. Consequently, further clinical evidence is required to confirm how these medications affect human fat tissue, potentially guiding more personalized obesity treatments based on overall metabolic status rather than weight control alone.
Worth a look